Literature DB >> 9833768

Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes.

L Mutti1, M T Valle, B Balbi, A M Orengo, A Lazzaro, P Alciato, E Gatti, P G Betta, E Pozzi.   

Abstract

Mesothelioma cells (MMc) are considered to be weakly immunogenic and the experimental approaches attempting to induce an immune response against these cells have been disappointing. Our aim was to investigate whether MMc possess the surface accessory molecules involved in antigen presentation and whether these cells are capable of presenting recall antigens to autologous blood lymphocytes. Four primary MMc cultures were generated from malignant effusions and examined to assess whether the accessory molecules required for antigen presentation were present on their surfaces. Intercellular adhesion molecule-I (ICAM-I; CD54); class I and class II major histocompatibility complex-DR (MHCI and MHCII-DR); B7-1 (CD80.3); and B7-2 (CD86) expression by MMc was studied by immunocytochemical and/or FACScan analysis. MMc were pulsed with purified protein derivative (PPD), Tetanus toxoid (TT) and Candida albicans (CA) bodies, and incubated with autologous lymphocytes. Lymphocyte proliferation was estimated by radionucleotide incorporation. Phenotypic analysis showed the presence of MHCII-DR, ICAM-I and B7-2 on primary MMc cultures, whereas the phenotypic evaluation of 2 established MMc lines did not show the presence of the B7-1 and B7-2 molecules. In addition, MHCII-DR was detectable only after interferon gamma (IFN-gamma) stimulation. Primary MMc cultures acquired the capability to induce lymphocyte proliferation after pulse with the recall antigens. To achieve characterization of these lymphocytes, we generated a PPD-specific CD4+ T-cell clone. PPD-pulsed MMc were shown to specifically induce T-cell clone proliferation through a MHCII-DR-mediated process. We conclude that primary MMc possess the surface molecules required for antigen presentation and can present recall antigens to CD4+ lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833768     DOI: 10.1002/(sici)1097-0215(19981209)78:6<740::aid-ijc12>3.0.co;2-5

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors.

Authors:  Joshua J Short; Chenthamarakshan Vasu; Mark J Holterman; David T Curiel; Alexander Pereboev
Journal:  Virus Res       Date:  2006-08-22       Impact factor: 3.303

2.  SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma.

Authors:  P Cacciotti; R Libener; P Betta; F Martini; C Porta; A Procopio; L Strizzi; L Penengo; M Tognon; L Mutti; G Gaudino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

3.  Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

Authors:  Peter G Maslak; Tao Dao; Lee M Krug; Suzanne Chanel; Tatyana Korontsvit; Victoria Zakhaleva; Ronghua Zhang; Jedd D Wolchok; Jianda Yuan; Javier Pinilla-Ibarz; Ellin Berman; Mark Weiss; Joseph Jurcic; Mark G Frattini; David A Scheinberg
Journal:  Blood       Date:  2010-04-16       Impact factor: 22.113

4.  Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.

Authors:  Riki Okita; Yuka Mimura-Kimura; Nobutaka Kawamoto; Naoki Yamamoto; Masashi Umeda; Masanori Okada; Hidetoshi Inokawa; Yusuke Mimura; Tomoyuki Murakami; Masao Nakata; Kazunori Okabe
Journal:  Cancer Immunol Immunother       Date:  2022-09-17       Impact factor: 6.630

5.  Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability.

Authors:  Yurong Song; Shaneen S Baxter; Lisheng Dai; Chelsea Sanders; Sandra Burkett; Ryan N Baugher; Stephanie D Mellott; Todd B Young; Heidi E Lawhorn; Simone Difilippantonio; Baktiar Karim; Yuwaraj Kadariya; Ligia A Pinto; Joseph R Testa; Robert H Shoemaker
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

Review 6.  Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.

Authors:  Lukasz Kuryk; Giulia Rodella; Monika Staniszewska; Katarzyna Wanda Pancer; Magdalena Wieczorek; Stefano Salmaso; Paolo Caliceti; Mariangela Garofalo
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

7.  Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells.

Authors:  Miho Murakami; Hideyo Ugai; Natalya Belousova; Alexander Pereboev; Paul Dent; Paul B Fisher; Maaike Everts; David T Curiel
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

Review 8.  Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

Authors:  Luciano Mutti; Tobias Peikert; Bruce W S Robinson; Arnaud Scherpereel; Anne S Tsao; Marc de Perrot; Gavitt A Woodard; David M Jablons; Jacinta Wiens; Fred R Hirsch; Haining Yang; Michele Carbone; Anish Thomas; Raffit Hassan
Journal:  J Thorac Oncol       Date:  2018-09       Impact factor: 15.609

9.  Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Authors:  Julija Hmeljak; Francisco Sanchez-Vega; Katherine A Hoadley; Juliann Shih; Chip Stewart; David Heiman; Patrick Tarpey; Ludmila Danilova; Esther Drill; Ewan A Gibb; Reanne Bowlby; Rupa Kanchi; Hatice U Osmanbeyoglu; Yoshitaka Sekido; Jumpei Takeshita; Yulia Newton; Kiley Graim; Manaswi Gupta; Carl M Gay; Lixia Diao; David L Gibbs; Vesteinn Thorsson; Lisa Iype; Havish Kantheti; David T Severson; Gloria Ravegnini; Patrice Desmeules; Achim A Jungbluth; William D Travis; Sanja Dacic; Lucian R Chirieac; Françoise Galateau-Sallé; Junya Fujimoto; Aliya N Husain; Henrique C Silveira; Valerie W Rusch; Robert C Rintoul; Harvey Pass; Hedy Kindler; Marjorie G Zauderer; David J Kwiatkowski; Raphael Bueno; Anne S Tsao; Jenette Creaney; Tara Lichtenberg; Kristen Leraas; Jay Bowen; Ina Felau; Jean Claude Zenklusen; Rehan Akbani; Andrew D Cherniack; Lauren A Byers; Michael S Noble; Jonathan A Fletcher; A Gordon Robertson; Ronglai Shen; Hiroyuki Aburatani; Bruce W Robinson; Peter Campbell; Marc Ladanyi
Journal:  Cancer Discov       Date:  2018-10-15       Impact factor: 39.397

10.  Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications.

Authors:  L Sigalotti; S Coral; M Altomonte; L Natali; G Gaudino; P Cacciotti; R Libener; F Colizzi; G Vianale; F Martini; M Tognon; A Jungbluth; J Cebon; E Maraskovsky; L Mutti; M Maio
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.